Exhibit 99.59
 
 Theratechnologies announces results for the third quarter 2010
Lower burn rate and solid financial position
 Montréal, Canada  October 12, 2010 www.theratech.com/en/investor-relations/financial-reports-theratechnologies.php www.sedar.com
 Third quarter financial highlights included
 Ø
    
    Consolidated revenues of $2,152,000Ø
    
    Burn rate of $2,629,000 and an adjusted burn rate of $4,340,000Ø
    
    Liquidity of $43,933,000 as at August 31, 2010
  Financial Highlights
  Ø
    
    Consolidated revenuesamounted to $2,152,000 for the quarter and $6,673,000 for the
nine-month period, compared to $13,148,000 and $17,474,000 for the corresponding periods in
2009. The higher revenues in 2009 are due to the receipt of a milestone payment of
$10,884,000 in the third quarter of 2009 associated with the U.S. Food and Drug
Administration (FDA) agreement to review the New Drug Application (NDA) for tesamorelin,
pursuant to the collaboration and licensing agreement with EMD Serono, Inc. (EMD Serono).Ø
    
    Research and development (R&D) expensesare significantly lower than those of the
previous year, reflecting the completion of the tesamorelin Phase 3 clinical program in 2009.
Before tax credits, R&D expenses totalled $2,930,000 for the quarter and $11,298,000 for the
nine-month period, compared to $5,681,000 and $17,692,000 for the corresponding periods in
2009, representing decreases of 48% and 36% respectively. The R&D expenses incurred in the
third quarter of 2010 are mainly related to the primary objective of the Company, which is to
obtain the regulatory approval of tesamorelin for the treatment excess abdominal fat in
HIV-infected patients with lipodystrophy in the United States.Ø
    
    General and administrative expensesamounted to $2,225,000 for the quarter and $6,083,000
for the nine-month period, compared to $1,337,000 and $5,515,000 for the corresponding
periods in 2009. The increase in general and administrative expenses is principally due to
professional fees associated with the recruitment of the new President and Chief Executive
Officer, a variation in stock-based compensation expense and foreign exchange rate
fluctuations. The higher expenses in the nine-month period are principally due to heightened
communication activities related to the FDA Advisory Committee meeting as well as an increase
in other administrative expenses partially offset by a reduction in the loss on foreign
exchange. The increase for the nine-month period is less, in relative terms, than that of the
third quarter because of costs associated with revising the Companys business plan incurred
in early 2009.
 Theratechnologies Inc.
  




---



##### 



Ø
    
    Selling and market development expensesamounted to $521,000 for the quarter and $1,901,000 for
the nine-month period compared to $495,000 and $1,516,000 for the corresponding periods in 2009.
The increase in the selling and market development expenses is principally due to business
development and market research studies for territories outside the United States. These
expenses also include activities associated with the management of the collaboration and
licensing agreement with EMD Serono.Ø
    
    Net lossrecorded by the Company was $3,277,000, representing $0.05 per share for the quarter
and $12,367,000 representing $0.20 per share for the nine-month period compared to net earnings
of $5,824,000 representing $0.10 per share and a net loss of $10,360,000 representing $0.17 per
share for the corresponding periods in 2009. The profit recorded in the third quarter of 2009
was due to the receipt of a milestone payment of $10,884,000 associated with the FDAs agreement
to review the NDA for tesamorelin, pursuant to the collaboration and licensing agreement with
EMD Serono.Ø
    
    Financial Position
 
    
    At August 31, 2010, liquidities, which include cash and bonds, amounted
to $43,419,000, and tax credits receivable amounted to $514,000, for a total of $43,933,000.
    
    The burn rate from operating activities, excluding changes in operating
assets and liabilities, was $2,629,000 in the quarter and $10,877,000 for the nine-month
period compared to a cash flow of $6,186,000 and a burn rate of $9,214,000 for the
corresponding periods in 2009. Excluding the revenues and fees associated with the agreement
with EMD Serono, the adjusted burn rate from operating activities, excluding changes in
operating assets and liabilities, was $4,340,000 in the quarter and $16,011,000 for the
nine-month period compared to $6,410,000 and $20,678,000 for the corresponding periods in
2009.
    
    In light of a lower expense level and cost control measures, the Company
anticipates that the adjusted burn rate for 2010 will be between $22,000,000 and $23,000,000,
and thus will be less than the initially forecasted adjusted burn rate of $24,000,000.
 Non-GAAP Measures
 Please refer to the
Managements Discussion and Analysis for the three- and nine-month periods ended August 31, 2010
for more details on how these non-GAAP measures are calculated.
 About Theratechnologies
  2




---



##### 



Additional Information about Theratechnologies
 www.theratech.com www.sedar.com
 Forward-Looking Information
     www.sedar.com
  3




---



##### 



Information:
 communications@theratech.com
 ltanguay@theratech.com
 4